Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial - The Lancet
PLOS ONE: Comparative Effectiveness of Intravenous Immunoglobulin for Children with Kawasaki Disease: A Nationwide Cohort Study
Could SARS-CoV-2 infection revisit the pathogenesis of Kawasaki disease?
Medicina | Free Full-Text | Clinical Manifestations of Kawasaki Disease at Different Age Spectrum: A Ten-Year Study | HTML
Clinical Practice Guidelines : Kawasaki disease
Recurrent Kawasaki disease and cardiac complications: nationwide surveys in Japan | Archives of Disease in Childhood
PDF) Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease
Refractory Kawasaki disease: diagnostic and management challenges | PHMT
Kawasaki Disease | PedsCases
RACGP - Kawasaki disease – the importance of prompt recognition and early referral
Kawasaki disease for dermatologists Gupta A, Singh S - Indian Dermatol Online J
Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study | Journal of the American Heart Association
Paediatric Kawasaki Disease - Clinical Analysis and Cases | Hong Wang | Springer
Cardiac Sequelae in Recurrent Cases of Kawasaki Disease: A Comparison Between the Initial Episode of the Disease and a Recurrence in the Same Patients | American Academy of Pediatrics
Kawasaki Disease Outcomes and Response to Therapy in a Multiethnic Community: A 10-Year Experience - The Journal of Pediatrics
While relatively rare, Kawasaki disease can be mistaken for other ailments and can damage heart if not treated - pennlive.com
Frontiers | Kawasaki Disease | Pediatrics
Cardiac Sequelae in Recurrent Cases of Kawasaki Disease: A Comparison Between the Initial Episode of the Disease and a Recurrence in the Same Patients | American Academy of Pediatrics
Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease | Scientific Reports
Cumulative recurrence rates of Kawasaki disease calculated by different... | Download Scientific Diagram
Epidemiology, Treatments, and Cardiac Complications in Patients with Kawasaki Disease: The Nationwide Survey in Japan, 2017-2018 - The Journal of Pediatrics
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
